Psoriasis News and Research RSS Feed - Psoriasis News and Research

Psoriasis is a chronic, immune-mediated disease that results from the overproduction of skin cells, resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that approximately 7.5 million Americans and nearly 3 percent of the world's population are living with psoriasis and nearly one-quarter of those people have cases that are considered moderate to severe.
Researchers find genetic mutations linked to increased risk factor for PTSD

Researchers find genetic mutations linked to increased risk factor for PTSD

In the largest study of DNA samples from service members with Post-Traumatic Stress Disorder (PTSD), researchers have identified genetic mutations that may be associated with an increased risk factor for PTSD. [More]
Penn State researchers link mutation in common virus to fatal brain disease

Penn State researchers link mutation in common virus to fatal brain disease

Why people on immunosuppressant drugs for autoimmune conditions have a higher incidence of an often-fatal brain disease may be linked to a mutation in a common virus, according to researchers at Penn State College of Medicine. [More]
Two statistically significant genetic variants may be linked to increased PTSD risk in veterans

Two statistically significant genetic variants may be linked to increased PTSD risk in veterans

In a massive analysis of DNA samples from more than 13,000 U.S. soldiers, scientists have identified two statistically significant genetic variants that may be associated with an increased risk of post-traumatic stress disorder (PTSD), an often serious mental illness linked to earlier exposure to a traumatic event, such as combat and an act of violence. [More]
People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

In a new University of Manchester study, people with psoriatic arthritis have told researchers about the condition's deeply damaging mental effects and how healthcare services failed to prepare them for its reality. [More]
Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy. [More]
New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
MALT1 inhibitors may be useful for treating psoriasis patients with CARD14 mutations

MALT1 inhibitors may be useful for treating psoriasis patients with CARD14 mutations

Psoriasis is a long-lasting autoimmune disease that is characterized by patches of abnormal and inflamed skin. It is generally thought to have a genetic origin, which can be further triggered by environmental factors. People with specific mutations in the CARD14 gene have a high probability of developing psoriasis. [More]
Taking antibiotics in early childhood can disrupt immune system function lifelong

Taking antibiotics in early childhood can disrupt immune system function lifelong

Scientists want to know whether taking antibiotics early in life can disrupt your immune system function lifelong. [More]
Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. [More]
Novel way of hitting prostate cancer

Novel way of hitting prostate cancer

Researchers at UC Davis, in collaboration with the other institutions, have found that suppressing the nuclear receptor protein ROR-γ with small-molecule compounds can reduce androgen receptor (AR) levels in castration-resistant prostate cancer and stop tumor growth. [More]
Alba’s Post takes new measures to help people with psoriasis

Alba’s Post takes new measures to help people with psoriasis

A new online platform, Alba’s Post, is taking new measures in helping people with psoriasis taking control of their disease, by providing information on the effects of nutrition. [More]
LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

LEO Pharma today announced that it received scientific approval of Enstilar (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment of psoriasis vulgaris in patients 18 years of age or older. [More]
Psoriasis patients experience widespread bone loss

Psoriasis patients experience widespread bone loss

Researchers from the Genes, Development and Disease Group, headed by Erwin Wagner at the Spanish National Cancer Research Centre have discovered that psoriasis patients experience a widespread bone loss as a result of the disease. [More]
Global research links genes to five common, hard-to-treat inflammatory diseases

Global research links genes to five common, hard-to-treat inflammatory diseases

A global study involving 50 different research centres has found hundreds of genes which cause five common, hard-to-treat and debilitating inflammatory diseases, paving the way to new treatments for these conditions [More]
Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Eli Lilly and Company announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab in a Phase 3 clinical trial. Detailed results of the UNCOVER-2 study were presented during the American Academy of Dermatology Annual Meeting taking place March 4-8 in Washington, D.C. [More]
Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Eli Lilly and Company announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for ixekizumab for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union who are candidates for systemic therapy. [More]
Remicade co-developer funds new microscopy facility on Scripps Florida campus

Remicade co-developer funds new microscopy facility on Scripps Florida campus

The co-developer of Remicade, one of the three top-selling drugs in the world, has donated more than $500,000 to fund what will be known as the Iris and Junming Le Foundation Super-Resolution Microscopy Facility on the Florida campus of The Scripps Research Institute. [More]
Certain viral infections during pregnancy could cause behavioral changes in offspring

Certain viral infections during pregnancy could cause behavioral changes in offspring

A study published in the journal Science found that activation in pregnant mice of a particular immune response, similar to what may occur with certain viral infections during pregnancy, alters the brain structure of the mouse offspring and causes behavioral changes, reminiscent of those observed in humans with autism spectrum disorder (ASD). [More]
Scientists solve atomic structure of ubiquitin ligase complex that plays key role in protein degradation

Scientists solve atomic structure of ubiquitin ligase complex that plays key role in protein degradation

Scientists at Sanford Burnham Prebys Medical Discovery Institute have solved the atomic structure of a unique ubiquitin ligase complex. Ubiquitin is best known for its role in protein degradation, but more recently seen as important for cell signaling, DNA repair, anti-inflammatory, and immune responses. [More]

Age plays key role when it comes to patients' access to most efficient psoriasis treatment

A new study from Umeå University in Sweden shows that age plays a huge role when it comes to patients' access to psoriasis treatment. Researchers who have examined if patients of varying ages have the same access to the most efficient psoriasis treatment, found that an age increase of 30 years resulted in an average 65 per cent reduction in likelihood of obtaining treatment with biologics. [More]
Advertisement
Advertisement